A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
| Condition | NSCLC, Breast Cancer |
|---|---|
| Phase | Phase 2 |
| Sponsor | Spectrum Pharmaceuticals, Inc |
| Status | Terminated |
| Enrollment | 7 participants |
| Interventions | Poziotinib |
| Start date | Oct 11, 2018 |
| Completion date | Mar 3, 2023 |
| Results posted | Jul 28, 2026 |
Summary
This is an open-label extension study (Extension Study) designed to allow patients to continue to receive poziotinib treatment who have had previous exposure to poziotinib and/or are still receiving clinical benefit from treatment, as judged by the Investigator or treating physician. Patients must begin treatment in this study within 28 days after their last dose of poziotinib. This extension protocol is intended to provide clinical benefit of poziotinib to patients who are responding to treatment. The additional treatment is optional and voluntary.
Number of Participants With Adverse Events (AEs)
| Poziotinib 6 mg | 1 Participants |
|---|---|
| Poziotinib 8 mg | 1 Participants |
| Poziotinib 12 mg | 1 Participants |
| Poziotinib 14 mg | 1 Participants |
| Poziotinib 16 mg | 2 Participants |
| Poziotinib 24 mg | 1 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Vitamin D and Physical Activity on Bone Health — University of Rochester
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in T — National Cancer Institute (NCI)
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Can — AstraZeneca
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Adm — University of Colorado, Denver